Phase 2Active, not recruiting
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years
- Sponsor
- Restorbio Inc. (Industry)
- Enrollment
- 60 planned
- Conditions
- Covid19
- Interventions
- RTB101; Placebo
- Ages
- older adults
- Registry
- NCT04584710
Full record on ClinicalTrials.gov
From the registry
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Primary outcomes
- To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years
History
Primary completion
Last registry update
Registered
Started